Lung cancer is the malignant tumor with the highest morbidity and mortality in China, and nonsmall cell lung cancer is a common form of lung cancer. After undergoing chemotherapy and molecular targeted therapy, the treatment of lung cancer has now fully entered the era of immunotherapy. Immunotherapy‐based treatment has become one of the standard treatments for lung cancer. Immunotherapy has also gradually moved from the back line to the front line, from advanced to early patients. This article focuses on the latest developments in perioperative and advanced lung cancer immunotherapy, discusses the problems and challenges at the current stage, and explores new directions for future development.

The current state of oncology medical services is not encouraging and is unable to fully meet the needs of patients with cancer. In recent years, rapidly developing artificial intelligence technology and gradual advancements in mobile phones, sensors, and wearable devices, which have made these more compact, affordable, and popular, have greatly expanded the development of digital medicine. Digital medicine refers to clinical evidence‐based technology and products with a direct impact on disease management and research. Integrating digital medicine into clinical practice has the advantages of broader applicability, greater cost‐effectiveness, better accessibility, and improved diagnostic and therapeutic performance. Digital medicine has emerged in different clinical application scenarios, including cancer prevention, screening, diagnosis, and treatment, as well as clinical trials. Additionally, big data generated from digital medicine can be used to improve levels of clinical diagnosis and treatment. However, digital medicine also faces many challenges, including security regulation and privacy protection, product usability, data management, and optimization of algorithms. In summary, the application and development of digital medicine in the field of cancer face numerous opportunities and challenges.